obesity News
-
The two sides of responsibility - a blog by Michael Prager
The Two Sides of Responsibility Listen to Glenn Beck ("Get away from my french fries, Mrs. Obama,” he’s reported to have said at an event in Illinois in September) or the lobbyists at the Center for Consumer Choice and you might come away thinking that the obesity epidemic in America is only a political issue: Nanny-state politicians vs. just plain folk. But it’s not nearly ...
By 3BL Media
-
The Additional Costs and Health Effects of a Patient Having Overweight or Obesity: A Computational Model
A new study published by The Obesity Society finds that being overweight can lead to financial costs. This is largely due to the need for more medical costs and loss of productivity caused by obesity. The research suggests that a 20-year-old who goes from being obese (BMI of 30 or higher) to overweight (BMI of 25 to 29.9) would save an average of $17,655 in direct medical costs and productivity ...
-
Campbell`s Soup does m`m...m`m good!
Alice Korngold's Blog “Business at its best: Maximizing long-term profitability and societal impact.” That’s the topic at the 6th Annual Board of Boards CEO Conference that will be held by the Committee Encouraging Corporate Philanthropy (CECP) in NYC later this month. Doug Conant, President and CEO of Campbell Soup Company, will join fellow CEOs of global corporations for this ...
By 3BL Media
-
Outpatient measurement of arterial stiffness in patients with type 2 diabetes and obesity
BACKGROUND: Pulse wave velocity (PWV) is a marker of arterial stiffness. The aim of the present study was to compare PWV in patients with type 2 diabetes mellitus (T2DM) or obesity and healthy subjects in an outpatient setting. METHODS: A cross-sectional study was conducted in patients with obesity without T2DM (n = 37), T2DM without obesity (n = 40), T2DM plus ...
By Axelife SAS
-
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming American Diabetes Association Scientific Sessions June 6, 2022
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the results of the Company's recently completed Phase 1 clinical trial of pemvidutide, an investigational GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH, will be presented in an oral presentation at the 82nd American Diabetes Association (ADA) Scientific ...
-
Altimmune to Present at Upcoming Investor Conferences
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences in May 2022: H.C. Wainwright Global Investment Conference Tuesday, May 24, 2022 7:00 am Eastern Time The session will be webcast and can be accessed by visiting the Events section of the Altimmune ...
-
Obesity Primes the Colon for Cancer, According to NIH Study
Obesity, rather than diet, causes changes in the colon that may lead to colorectal cancer, according to a study in mice by the National Institutes of Health. The finding bolsters the recommendation that calorie control and frequent exercise are not only key to a healthy lifestyle, but a strategy to lower the risk for colon cancer, the second leading cause of cancer-related death in the United ...
-
ReShape Lifesciences Receives USPTO Issue Notification for Patent Covering its ReShape Vest
ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announces that the United States Patent and Trademark Office (“USPTO”) has issued an Issue Notification for U.S. Patent Number 10010441 entitled “Gastric Restriction Device for Treating Obesity,” which covers a patent application ...
-
Altimmune to Present Pemvidutide Clinical Data at Upcoming Global NASH Congress May 27, 2022
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will give an oral presentation at the 5th Global NASH Congress on May 26-27, 2022, in London, UK. His presentation will provide an overview of pemvidutide, the Company’s novel, investigational GLP-1/glucagon dual receptor agonist under ...
-
Altimmune to Participate at Two Upcoming Investor Conferences
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences in June 2022: Jefferies 2022 Global Healthcare Conference in New York, NY Friday, June 10, 2022 Fireside chat at 10:00 am Eastern Time JMP Securities Life Sciences Conference in New York, NY ...
-
Camurus announces dosing initiated in Phase 3 trial of weekly setmelanotide in patients with genetic obesity disorder
Camurus (NASDAQ STO: CAMX) today announces that the company’s license partner Rhythm Pharmaceuticals has dosed the first patients in a Phase 3 trial evaluating weekly setmelanotide subcutaneous depot in patients six years of age and older with a rare genetic disease of obesity. “We are pleased with the progress of our collaboration with Rhythm and today’s announcement of the ...
By Camurus AB
-
NFL PLAY 60 and volunteermatch partner to encourage adults to volunteer for kids` health and wellness
NFL PLAY 60 has teamed up with VolunteerMatch, the Web's most popular volunteering network, to help make it easier for fans to discover volunteer opportunities in the youth health and wellness space. The NFL PLAY 60 VolunteerMatch Web site is now accessible at http://www.nflrush.com/play60. At the site, interested parties may find local volunteer opportunities from VolunteerMatch's national ...
-
National non-profit KaBOOM! lauches CSR campaign to `save play` for a million kids this year
National nonprofit KaBOOM! is dedicated to saving play. Few people realize that play is in peril. Play is quickly disappearing from children's lives, and it's taking a toll on the health and happiness of children, families and communities. So, to help take this critical issue head on, KaBOOM! is calling on its corporate and individual friends to support its new campaign to "Save Play" by taking ...
-
Alexis Glick named CEO of Gen YOUth foundation
Alexis Glick, a former Fox Business executive, Today anchor, financial executive and a mother of three, will bring extensive experience in branding, media and finance to an important new role: CEO of the Gen YOUth Foundation. This new nonprofit organization will give leaders in health, business, government and communities nationwide the opportunity to be a part of a movement that relies on ...
-
Belfast Newsletter - Health tech company creates 22 new jobs
Neurovalens, a global leader of neuro-technology products, is embarking on the development of a device for the treatment of obesity with £1m support from Invest NI. The technology is based on the neuro stimulation of specific areas of the brain responsible for influencing appetite and cravings. The company specialises in combining neuroscience and technology to tackle global health ...
-
Buy-out of the Helioscopie company by the Santé Actions group
On October 26, 2010, Helioscopie, an expert company in medical implants in the obesity field located in Vienne, France (38), came under new direction. The Santé Actions group took control of the company. Dr. Sauveur Ferrara will hold the office of President. Dr. Ferrara, the President and founder of the Santé Actions group, a company specialized in health and medico-social care, is ...
-
GI Dynamics Announces Approval of the I-STEP Clinical Study in India
BOSTON & HYDERABAD, India--( )-- GI Dynamics Inc., a medical device company that isBUSINESS WIRE developing the EndoBarrier® System for patients diagnosed with type 2 diabetes and obesity, is pleased to announce that it has received regulatory approval to begin enrollment in the I-STEP clinical trial in India. I-STEP is a multi-center, randomized, pivotal study evaluating the safety and ...
-
Dieters wanted for website trial
The CSIRO Preventative Health Flagship is calling for volunteers to try out a pilot ‘online social network’ in which they get access to free diet and health information, recipes and chat sessions. CSIRO is asking participants to sign up for 12 weeks, starting in early August. CSIRO ICT research scientist Dr Shlomo Berkovsky said the trial aims to understand how online tools, such as ...
-
ReShape Lifesciences Announces Stocking Order from Medical Supplier in Dubai
ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases announced today that it has received a significant order for its ReShape® Integrated Dual Balloon System from Al Zahrawi Medical a healthcare focused company specializing in medical, surgical, diagnostic and analytical lab and nuclear medicine supplies with ...
-
Altimmune Announces Initiation Of 48-Week Phase 2 MOMENTUM Trial Of Pemvidutide In Obesity
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has enrolled the first subject in the 48-week Phase 2 MOMENTUM trial evaluating the safety and efficacy of pemvidutide1 in subjects with obesity or overweight. Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of obesity and ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you